360 These are listed in appendix I, with reasons for exclusion given. See also the health economic study selection flow chart in appendix D. Monitoring Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Table 96: Health economic evidence profile: Structured telephone support vs telemonitoring vs usual care Study Applicability Limitation s Other comments Costs (a) Effects (a) Incremental cost (b) Incremental effects (b) Cost effectiveness (b) Uncertainty Pandor [Thokala ] Directly applicable (c) Potentially serious limitations (d) Cost-utility analysis Comparators: 1. Usual care 2. Structured telephone support human to machine interface 3. Structured telephone support human to human interface 4. Home telemonitoring Clinical data determined from a NMA of RCT data Lifetime horizon 6 month intervention, after which receive usual care. effects) Prob. CE: 5% at Prob. CE: 12% threshold QALY gained Prob. CE: 83% threshold Abbreviations: CE: cost effective; ICER: Incremental Cost Effectiveness Ratio; NMA: network meta-analysis; QALY: quality-adjusted life years; RCT: randomised controlled trial (a) Cost/effect in order of least to most costly intervention. (b) Full incremental analysis of available strategies: first strategies are ruled out that are dominated (another strategy is more effective and has lower costs) or subject to extended dominance (the strategy is more effective and more costly but the incremental cost effectiveness ratio is higher than the next most effective option and so it would never be the most cost effective option); incremental costs, incremental effects and incremental cost effectiveness ratios are calculated for the remaining strategies by comparing each to the next most effective option. (c) Assesses structured telephone support with human to machine contact and human to human contact separately. 